Long Covid - A Comprehensive Review of Post-Acute Sequelae of Covid-19

Maharsh Jani

Abstract

Diving into the depths of medical mysteries, Long Covid, a perplexing phenomenon with the alternative nomenclature of Post-Acute Sequelae of SARS-CoV-2 infection (PASC), unveils its enigmatic nature. This condition, veiled in the aftermath of resolved acute COVID-19, unravels a tapestry of persistent symptoms that mercilessly haunt its victims. Fatigue, shortness of breath, cognitive impairment, and a host of other maladies emerge, casting a dark shadow upon the once-vibrant lives of patients.

A comprehensive expedition awaits as this review article endeavors to shed light on the intricate web of Long Covid, its pharmacological interventions, both present and under scrutiny in clinical trials. But let us not confine ourselves solely to the immediate realm of suffering; let us broaden our horizons and contemplate the far-reaching consequences of Long Covid, both on individuals and the healthcare system at large.

Within these convoluted lines lies a quest to unravel the diagnostic quandaries and management conundrums of Long Covid. As the research compass diligently points towards a more profound comprehension of this nascent condition, the journey towards enlightenment marches forward unabated. This review paper aims to consolidate the current knowledge, explore unresolved questions, and provide insights into the diagnostic approaches and management strategies for Long Covid. By delving into the underlying mechanisms and exploring potential therapeutic avenues, this abstract serves as a precursor to the comprehensive exploration of Long Covid in the subsequent sections of this review.

Keywords

Long-Covid; Covid-19; PASC; SARS-CoV-2; Corona-Virus

Introduction

In the annals of history, a momentous news briefing unfolded on the fateful day of March 11, 2020. Dr. Tedros Adhanom Ghebreyesus, the esteemed Director-General of the World Health Organization (WHO), stood before the world, his words laden with gravity, as he declared the outbreak of COVID-19 a formidable global pandemic (Cucinotta et al., 2020). The stage was set, the curtains drawn, and humanity bore witness to the unfolding drama sparked by the emergence of a novel adversary—SARS-CoV-2. This elusive virus, born in the depths of China in the year 2019, stealthily traversed borders, spanning continents with its insidious grip, leaving no

corner of the world untouched. Its unwavering presence continues to cast a shadow of uncertainty over the collective consciousness of humanity.

Delving into the intricate realm of genetic code, a meticulous analysis of the complete viral genome of SARS-CoV-2 unveils a staggering revelation. This viral entity, composed of a staggering 29,903 nucleotides, bears a striking resemblance to a cohort of SARS-like coronaviruses hailing from the illustrious genus Betacoronavirus and the distinguished subgenus Sarbecovirus. Intriguingly, these coronaviruses had previously been unearthed in the depths of the bat population residing within the borders of China (Wu et al., 2020). Such a genetic kinship, with a nucleotide similarity reaching a formidable 89.1%, points to a profound hypothesis—the genesis of SARS-CoV-2 likely transpired within the ethereal realms of bats or other unsuspecting animals, before executing a daring leap into the realm of humanity. This enigmatic process, known as zoonotic spillover, stands as a testament to the intricate dance between species, a fateful encounter that would shape the course of history.

Within the relentless grip of the ongoing COVID-19 outbreak, a resounding alarm echoes through the corridors of scientific understanding—a stark reminder of the perils posed by zoonotic spillover events. In these fateful encounters, viruses masterfully traverse the boundaries between animal and human realms, instigating a cataclysm of severe diseases. The tableau of this crisis casts a glaring spotlight on the urgent necessity for unwavering surveillance of zoonotic diseases. Vigilance becomes the watchword as we strive to preempt and curtail their insidious spread. To combat this ever-looming threat, a multifaceted approach takes center stage—one that embraces the tenets of early detection and rapid response. Equipped with the arsenal of effective treatments and fortified by the formidable shield of vaccines, humanity stands poised to confront the untamed forces of nature. It is in this harmonious interplay of foresight and action that we endeavor to safeguard our collective well-being and chart a path towards a resilient future.

Amidst the swirling tides of uncertainty, the emergence of COVID-19 as an unprecedented disease thrusts humanity into uncharted territory. In the face of this daunting challenge, the imperative to forge new frameworks and navigate unexplored decision-making landscapes becomes paramount. A clarion call resounds throughout the global community, beckoning relevant stakeholders to a momentous gathering—a global consultation of minds. United in purpose, these disparate voices converge, driven by the shared understanding of the urgent necessity to facilitate the seamless flow of timely information on the perplexing tapestry of SARS-CoV-2 variants. The potential ramifications of these variants on public health interventions loom large, demanding a swift and coordinated response. This pivotal consultation serves as the inaugural step, a cornerstone upon which effective collaboration and synchronized efforts shall be built.

Together, humanity strives to unravel the enigma, surmount the challenges, and chart a course towards the effective management of this relentless pandemic.

In the vast tapestry of the global COVID-19 pandemic, the imperative of inclusivity unfurls its wings, beckoning all nations to converge in a united front against the relentless spread of this disease. A symphony of collaboration ensues, as the timeless virtues of shared knowledge, pooled resources, and collective expertise resonate throughout the global community. With unwavering determination, we embrace the call to action, recognizing that timely and efficient information exchange is the lifeblood of our collective defense. By weaving the threads of cooperation, we can forge formidable strategies that aim to curtail the impact of COVID-19 and its myriad variants on the public health landscape. In this grand pursuit, the health and well-being of communities across the globe ascend to the apex of our collective consciousness. Grounded in the fertile soil of evidence-based approaches, fortified by the latest scientific knowledge and best practices, we march forward with resolute steps towards a future safeguarded by the indomitable spirit of collaboration.

Within the intricate tapestry of public health, an ever-present specter looms—severe acute respiratory syndrome (SARS), Zika virus disease, and a legion of emerging infectious diseases. These enigmatic adversaries, shrouded in mystery, cast their ominous shadow upon the collective well-being of humanity. Despite the valiant efforts of tireless researchers, the origins, timing, and geographical footprints of these novel afflictions remain veiled in uncertainty, perpetuating an aura of unpredictability (Wu et al., 2020). It is within this realm of profound uncertainty that the clarion call for unwavering surveillance and diligent monitoring of emerging infectious diseases resounds with unwavering urgency. Through a vigilant watchfulness, we strive to pierce the shroud of ambiguity and illuminate the pathways of these stealthy invaders. Armed with the weapons of knowledge and foresight, we endeavor to forge effective prevention and control measures that stand as bastions against the tide of uncertainty. In this ever-evolving battle, the relentless pursuit of understanding intertwines with the steadfast commitment to safeguarding public health. Together, we strive to navigate the labyrinth of emerging diseases, guided by the flickering torch of science, as we inscribe the story of resilience and protection upon the annals of humanity.

Amidst the ever-shifting landscape of new diseases, a formidable presence emerges, casting its shadow upon the realm of human health—Long Covid, a moniker bestowed upon the post-COVID conditions that unfold in the aftermath of the pandemic. Within this intricate tapestry of long-term consequences, a symphony of debilitating symptoms takes center stage, leaving in its wake a trail of fatigue, breathlessness, and cognitive haze, among other afflictions. Long Covid transcends the realm of mere discomfort, stepping into the realm of disability under the revered Americans with Disabilities Act

(ADA). This classification serves as a stark reminder of the profound impact that COVID-19 can inflict upon individuals and communities alike. As we navigate the uncharted waters of the ongoing pandemic and brace ourselves for the onslaught of future emerging infectious diseases, a clarion call resounds—a call to prioritize the holistic well-being of all individuals, especially those who find themselves more vulnerable to the enduring effects of these diseases. To answer this call, we must invest our collective efforts in research, channeling resources towards unraveling the enigma of Long Covid and other post-infectious conditions. In doing so, we forge a path towards understanding and managing these intricate conditions, safeguarding the health and resilience of our global community.

General Idea of Long Covid

Post-acute sequelae of SARS-CoV-2 (PASC), a complex entity that also goes by the names of Post-Covid Syndrome and Long Covid, unfurls its enigmatic nature before us. Within the fabric of this condition, a constellation of signs and symptoms persists, defying the boundaries of time, extending its grasp for weeks or even months beyond the initial encounter with the nefarious SARS-CoV-2 virus (Mantovani et al., 2022). PASC, a multifaceted condition, ventures beyond the confines of a single organ system, permeating through the pulmonary pathways, intricately entwining with the neurological networks, resonating within the chambers of the cardiovascular system, leaving an indelible mark upon the delicate intricacies of the kidney, and even manifesting its presence within the neuromuscular tapestry, among other realms. Its formidable presence echoes through the corridors of the human body, heralding a prolonged battle against the aftermath of the initial viral encounter. As we unravel the threads of this complex phenomenon, we inch closer to understanding the intricate web of Long Covid, a journey that holds promise for improved management and enhanced quality of life for those affected.

Within the vast landscape of post-acute sequelae of SARS-CoV-2 (PASC), a remarkable revelation emerges, etching a profound mark upon our understanding. Extensive studies unveil a disquieting truth—the prevalence of PASC transcends mere rarity, ensnaring more than 10% of individuals who have endured the acute phase of SARS-CoV-2 infection, entangling them within its intricate web of signs and symptoms (Mantovani et al., 2022). This revelation reverberates through the collective consciousness, shedding light on the enduring impact that COVID-19 can impose upon individuals long after the initial infection has abated. The implications of PASC are far-reaching, beckoning us to dedicate unwavering resources and boundless research endeavors to unravel its enigmatic nature. As we delve deeper into the labyrinthine corridors of post-infectious conditions, the significance of continued investigation

becomes ever more apparent. It is through this relentless pursuit of knowledge and the provision of adequate resources that we forge a path towards improved understanding and management of PASC and other allied afflictions. In embracing the mantle of scientific inquiry, we lay the groundwork for a future that promises enhanced well-being and fortified resilience for those traversing the arduous terrain of post-infectious conditions.

Effect of Long Covid

In the midst of the relentless battle against the ongoing COVID-19 pandemic, a beacon of hope illuminates our path. Recent research, a testament to the tireless endeavors of scientific exploration, unravels a profound truth—vaccination stands as a formidable ally in our quest to mitigate the risk and severity of post-acute sequelae of SARS-CoV-2 (PASC) following breakthrough infections (Mantovani et al., 2022). This revelation cascades through the collective consciousness, underscoring the critical importance of widespread vaccination efforts. As we strive to navigate the tumultuous seas of the pandemic and its aftermath, a resounding call to action resounds—a call to prioritize the holistic well-being of all individuals, especially those who may bear the burden of vulnerability to the long-term effects of this relentless disease. Embracing the power of vaccination, we fortify our defenses, shielding ourselves and our communities from the enduring impact of COVID-19. In this shared pursuit, the health and resilience of our global family stand at the forefront, beckoning us to unite and chart a course towards a future illuminated by the rays of protection, compassion, and collective well-being.

Lungs

In the realm of post-acute sequelae of SARS-CoV-2 (PASC), the profound impact on the pulmonary system emerges as a focal point of concern. As illuminated by Mantovani et al. (2022), this intricate condition, also known as Post-Acute Sequelae of SARS-CoV-2, casts its shadow upon the delicate tapestry of the respiratory realm. Within this complex interplay, a triad of symptoms takes center stage, heralding the presence of dyspnea, chest pain, and cough as the prevailing manifestations. It is within the realm of the pulmonary landscape that the effects of PASC are most keenly felt. Notably, those individuals burdened with comorbidities find themselves perched upon the precipice of vulnerability, their lung function standing as a fragile sentinel against the ravages of this enduring condition. Even in the wake of hospital discharge, the echoes of respiratory distress persist, resonating within the corridors of fatigue, dyspnea, chest pain, and cough. The endurance of these symptoms spans a formidable period, spanning from three weeks to three months post-infection, casting a lingering shadow upon the affected individuals. In shedding light upon these manifestations, we uncover the

immense burden imposed by PASC upon the respiratory domain, driving us towards a deeper understanding and enhanced management of this multifaceted condition.

Within the intricate landscape of post-acute sequelae of SARS-CoV-2 (PASC), a complex tale unfolds, illuminating the lives of individuals who have traversed the arduous path of COVID-19 recovery, only to be ensnared by the enduring grip of persistent symptoms. PASC, a formidable foe, manifests itself in a variety of ways, casting a shadow upon the delicate fabric of existence. Amidst this multifaceted condition, the pulmonary realm becomes a battleground where the echoes of distress resonate. Dyspnea, chest pain, and cough emerge as the prevailing protagonists, weaving their intricate tapestry of pulmonary manifestations. The burden borne by those afflicted is not to be underestimated, as these symptoms exact a toll upon their quality of life, leaving them in the throes of debilitation. It is within this domain that a poignant revelation surfaces—decreased lung function, a haunting specter, has been observed in patients grappling with underlying health conditions, exacerbating their vulnerability to the encompassing grip of PASC. As we unravel the complex interplay of this condition, we draw closer to a comprehensive understanding of its profound impact on the pulmonary realm, propelling us towards greater insights and strategies to enhance the quality of life for those ensnared within the clutches of PASC.

Beyond the confines of hospital walls, the echoes of respiratory distress persist, weaving a tapestry of enduring symptoms that reverberate through the lives of those grappling with post-acute sequelae of SARS-CoV-2 (PASC). Fatigue, dyspnea, chest pain, and cough continue to cast their shadow upon the path to recovery, refusing to relent even after the moment of hospital discharge has passed. The enduring prevalence of these respiratory symptoms bears witness to the profound impact they wield upon the patient's journey towards healing and holistic well-being. As we navigate the realm of PASC, a resounding call to action emerges—a call to vigilantly monitor and effectively manage these persistent manifestations. By doing so, we strive to minimize the long-term effects that PASC can inflict upon the delicate pulmonary system. Through our concerted efforts, we forge a path towards comprehensive care, guiding patients along a trajectory that holds promise for improved recovery and sustained respiratory health.

Cardiovascular

Within the realm of COVID-19's impact on the cardiovascular domain, a disquieting truth emerges from the meticulous exploration conducted by Mantovani et al. (2022). Among the symphony of symptoms that resonate through the afflicted individuals, inflammation takes center stage—a phenomenon known as myocarditis. This affliction, an

inflammatory cascade that ensnares the heart, unfurls its disruptive tendrils within the intricate tapestry of COVID-19-related complications. The incidence of COVID-19-associated myocarditis casts a somber shadow, revealing a prevalence of approximately 150 cases per 100,000 individuals within the general population. The gravity of this condition is not to be understated, for it unveils a landscape where the harmonious rhythms of the heart are disrupted, paving the way for potential complications that span heart failure, arrhythmias, and an array of cardiac tribulations. As we delve deeper into the complexities of COVID-19's impact on the cardiovascular system, we are beckoned to adopt an unwavering commitment to understanding and managing the ramifications of myocarditis, ushering in a future where comprehensive care and vigilance guard against its enduring toll.

In the realm of COVID-19's impact on the vulnerable terrain of adolescence, the groundbreaking research conducted by Szarpak et al. (2022) casts a poignant spotlight upon a concerning revelation. Within the age group of 12-17, teenagers stand at a crossroads of vulnerability, as the specter of myocarditis looms within 3-4 months of contracting COVID-19. The findings of this study serve as a clarion call, underscoring the critical importance of vigilance and early detection in the realm of myocarditis among this demographic. It is within the crucible of monitoring that we hold the power to unravel the subtle intricacies of this affliction, enabling timely intervention and mitigating the potential consequences that lie in wait. As we navigate this uncharted territory, guided by the insights gleaned from Szarpak et al.'s research, we arm ourselves with knowledge, determination, and a steadfast commitment to safeguarding the well-being of teenagers. Through our collective efforts, we forge a path towards vigilant surveillance and proactive measures, seeking to shield this vulnerable population from the enduring impact of myocarditis.

The gravity of myocarditis as a formidable complication stemming from the clutches of COVID-19 cannot be overstated. Within the intricate landscape of this affliction, the heart becomes a vulnerable canvas upon which its long-lasting impact is imprinted. To navigate this treacherous territory, a steadfast awareness of the symptoms associated with myocarditis becomes paramount. The telltale signs of this condition, such as chest pain, shortness of breath, fatigue, and palpitations, serve as harbingers, beckoning individuals to heed their call and promptly seek medical attention. By embracing a proactive approach, we harness the power to potentially mitigate the long-term damage that can ensue. Moreover, it is essential to recognize the interplay between myocarditis and underlying health conditions, for they can converge to heighten the risk. Conditions such as hypertension, diabetes, and obesity form an intricate tapestry of vulnerability, casting individuals into a realm where the stakes are raised. By actively monitoring and managing these underlying health conditions, we fortify our defenses, creating a shield against the insidious grip of myocarditis. Through a collaborative effort that intertwines

vigilance, awareness, and effective management, we strive to protect the sanctity of the heart and navigate a path towards lasting well-being.

Neuromuscular

Within the intricate tapestry of Post-Acute Sequelae of SARS-CoV-2 (PASC), a symphony of symptoms unfolds, revealing a landscape imbued with the profound impact of this enduring condition. Muscle weakness, fatigue, and exercise intolerance emerge as stalwart companions, etching their presence upon the lives of those grappling with the aftermath of SARS-CoV-2 infection. This trio of symptoms casts a shadow upon the path to recovery, imposing limitations and reshaping the contours of daily existence. Furthermore, the realm of myalgia reveals itself, as aches and pains persist, extending their reach over the course of weeks or even months. As we delve deeper into the enigmatic realm of PASC, a striking similarity emerges—a kinship with Chronic Fatigue Syndrome (CFS), also known as myalgic encephalomyelitis (ME). The symptoms shared by these two conditions intertwine, blurring the boundaries that separate them. In the realm of PASC, we confront a convergence of experiences, forging a path towards comprehensive understanding and care. By recognizing the parallels between PASC and CFS/ME, we embrace an approach that fosters empathy, research, and tailored interventions, empowering individuals to traverse the intricate terrain of these interconnected conditions.

Chronic Fatigue Syndrome (CFS), also known as myalgic encephalomyelitis (ME), weaves a narrative of enduring challenges within its chronic embrace. Anchored by the unrelenting presence of persistent fatigue, this complex condition unfurls its reach to encompass a myriad of symptoms. Sleep disturbances disrupt the restful embrace of slumber, while cognitive impairment casts a fog over the realm of clarity. The interplay of muscle and joint pain serves as a reminder of the intricate relationship between mind and body. As we explore the labyrinthine realm of Post-Acute Sequelae of SARS-CoV-2 (PASC), a shared tapestry with CFS/ME reveals itself. Patients who find themselves traversing the realm of PASC, encountering symptoms reminiscent of CFS/ME, warrant a tailored approach to their care and management. Specialized attention, rooted in empathy and expertise, becomes paramount. The need to seek medical attention when these symptoms persist or escalate over time becomes an imperative, guiding individuals towards the support and intervention they require. By embracing a comprehensive understanding of the overlapping territories of PASC and CFS/ME, we take strides towards alleviating the burdens carried by those whose lives are shaped by the relentless grip of these conditions.

Within the intricate landscape of the Post-Acute Sequelae of SARS-CoV-2 (PASC), healthcare providers stand as beacons of knowledge and empathy, armed with the understanding of the potential long-term consequences that linger in its wake. They assume a pivotal role in this narrative, as they traverse the path alongside their patients, offering solace, guidance, and tailored care. A profound awareness of the enduring impact of PASC underscores the importance of forging an individualized care plan, meticulously tailored to address the unique needs of each patient. Through open communication and collaborative decision-making, healthcare providers and patients become partners on this transformative journey. By harnessing the power of personalized care, the management of PASC symptoms emerges as a beacon of hope, enabling patients to navigate their recovery with greater swiftness and resilience. This vigilant approach not only expedites the healing process but also serves as a shield, warding off the specter of long-term complications that can cast a shadow over the horizon. By embracing this profound connection between patient and provider, we illuminate a path that leads to improved quality of life, empowering individuals to reclaim their vitality and forge ahead with renewed strength and purpose.

Nervous System

Within the intricate realm of Post-Acute Sequelae of SARS-CoV-2 (PASC), a symphony of diverse afflictions resonates, transcending the boundaries of the physical and venturing into the realms of cognition, neurology, and psychiatry. In this multifaceted landscape, a tapestry of distressing symptoms emerges, weaving together a complex narrative. Memory loss, a fragmentary tapestry of recollection, intertwines with the embrace of fatigue, casting a veil upon the path to vitality. Anosmia, the loss of the olfactory realm, robs the senses of their aromatic tapestry, while dysgeusia, the loss of taste's delicate nuances, alters the symphony of flavors that once delighted the palate. These symptoms, borne by the ebbs and flows of PASC, extend their grasp over weeks and months, a testament to their persistence. They do not discriminate, for any individual can find themselves ensnared within their grasp. It is through a comprehensive understanding of these manifestations, grounded in research and empathy, that we embark on a journey towards alleviating the burdens carried by those touched by PASC. By recognizing the intricate interplay between physical and cognitive realms, we forge a path towards tailored interventions, informed support, and a renewed commitment to the restoration of wellbeing.

Embedded within the tapestry of Post-Acute Sequelae of SARS-CoV-2 (PASC), a vast expanse of neurological terrain unfurls, revealing a mosaic of intricate symptoms that reverberate through the corridors of the mind. Headaches, like thunderclaps in the realms of thought, echo their presence, casting shadows upon the canvas of

consciousness. Dizziness, an unsteady dance, disrupts the harmony of equilibrium, leaving individuals caught in a delicate sway. Concentration and memory, once steadfast allies, falter and wane, drifting amidst the fog that veils cognitive clarity. Amidst this labyrinth of neurological manifestations, the specter of psychiatric disorders looms, casting its own ethereal hue. Depression, a cloak of shadows that eclipses the light, descends upon weary shoulders, while anxiety, a tempest within, weaves its own intricate tale. These symptoms, interwoven within the fabric of PASC, bear witness to the profound impact they can wield upon the daily tapestry of life. Recognizing and addressing these neurological and psychiatric companions becomes an imperative, guiding healthcare providers on a path of understanding and intervention. By embracing this holistic perspective, we illuminate a path that leads to comprehensive support, restoring equilibrium, and nurturing the delicate resilience of the mind.

Within the realm of Post-Acute Sequelae of SARS-CoV-2 (PASC), a curious and enigmatic phenomenon unfolds, intertwining the delicate senses of smell and taste in its narrative. The ethereal dance of aromas and flavors, once a vibrant tapestry of sensory delights, is disrupted, leaving behind a void. The loss of these precious senses, a haunting echo of the acute illness that has transpired, can persist with steadfast resolve, transcending the boundaries of time. This enduring absence casts its shadow upon the patient's existence, reshaping their perception of the world. The vibrant bouquet of scents that once stirred emotions lies dormant, and the symphony of tastes that once brought joy now remains muted. This profound loss, a testament to the intricate interplay between the virus and the delicate receptors, warrants further evaluation and treatment. It is through this exploration of the unseen, guided by empathy and expertise, that we strive to restore the vibrancy of sensory experience and rekindle the flames of joy that reside within the realm of scent and taste.

In the multifaceted landscape of Post-Acute Sequelae of SARS-CoV-2 (PASC), a tapestry of symptoms intertwines, necessitating a holistic and multidisciplinary approach to its management. Healthcare providers, like skilled artisans, weave together an intricate blend of strategies to navigate the complexities of this condition. Through the fusion of medication, physical therapy, and behavioral interventions, a symphony of care emerges, tailored to the unique needs of each individual traversing the path of PASC. Medications, like keystones in the archway of healing, may offer solace and respite from the grip of symptoms. Physical therapy, a gentle guide through the labyrinth of rehabilitation, empowers the body's innate resilience, restoring strength and function. Behavioral interventions, a tapestry of understanding and support, nurture the intricate interplay of mind and body, fostering a foundation of well-being. Yet, amid this orchestration of care, a symphony is incomplete without vigilant monitoring and continuous communication. Through this harmonious exchange, healthcare providers and patients forge a bond, embarking on a journey of shared understanding and

collaboration. As they navigate the twists and turns of PASC, they stand united, embracing the ever-evolving nature of this condition and forging a path toward the best possible outcomes.

Effect of Long Covid.

Long COVID, with its enigmatic nature, can manifest through various mechanisms, each adding a layer of complexity to our understanding. Within this intricate tapestry of post-acute sequelae, the persistence of the SARS-CoV-2 virus stands as a potential culprit. It has been suggested that viral remnants, like fading echoes of a bygone symphony, may linger within the body, evoking a prolonged immune response. Another melody in this intricate composition is the notion of SARS-CoV-2 superantigen-mediated activation of the immune system, where a discordant chorus of immune cells may unwittingly perpetuate the symptoms of long COVID.

The symphony deepens further with the emergence of autoimmunity, where the body's harmonious symphony turns discordant, playing a cacophony of self-directed attacks. In this intricate dance, B cells exhibit a continuous evolution, their melodies of response undergoing somatic hypermutation long after the initial infection has waned. Remarkably, even after months have passed, the SARS-CoV-2 nucleocapsid protein may persist, hidden within the depths of intestinal biopsies.

Echoes of the virus have been found to reverberate through time, persisting within the lungs of a transplant donor who triumphed over COVID-19, and within the skin biopsies of those bearing the peculiar mark of "COVID-toes." These lingering traces of the virus, like whispers in the wind, persist long after standard PCR tests may render a person negative.

As the symphony of Long COVID continues to unfold, these potential reservoirs of viral persistence, immune activation, and autoimmunity demand our attention. They underscore the need for further exploration, for it is through unraveling these intricate melodies that we may harmonize the discordance and find the key to alleviating the burdens of long COVID.

Within the complex interplay between SARS-CoV-2 and the immune system, the notion of superantigen-mediated stimulation emerges as a potential mechanism contributing to the pathogenesis of certain COVID-19 related conditions. Structural modeling has shed light on a potential superantigen motif located near the S1-S2 cleavage site of the SARS-CoV-2 spike protein, offering a glimpse into the intricacies of viral-host interactions.

To further bolster the plausibility of superantigen-mediated stimulation, the expansion of TRBV21-3+ cells has been observed in patients with Multisystem Inflammatory Syndrome in Children (MIS-C), providing indirect support for this phenomenon. This expansion of specific T-cell populations echoes the patterns seen in other conditions triggered by superantigens, such as staphylococcal toxic shock syndrome, where certain staphylococcal strains elicit a widespread and excessive immune response through the activation of T cells.

This parallel with other pathogenic entities that induce toxic shock syndrome adds another layer of complexity to our understanding of the immune response in COVID-19. It suggests that SARS-CoV-2, in its intricate dance with the immune system, may engage superantigenic mechanisms, leading to aberrant immune activation and subsequent clinical manifestations.

As the symphony of research continues to unveil the intricacies of SARS-CoV-2 and its interactions with the immune system, the exploration of superantigen-mediated stimulation provides a captivating avenue for further investigation. By delving deeper into this phenomenon, we may gain valuable insights into the pathogenesis of COVID-19-related conditions, allowing for the development of targeted therapeutic strategies to alleviate the burden on affected individuals.

Symptoms of Long Covid

Long Covid, a complex and multifaceted condition that follows the acute phase of SARS-CoV-2 infection, manifests with a wide array of symptoms that can greatly impact individuals' daily lives. Among these symptoms, fatigue stands out as the most prevalent, affecting nearly 47% of Long Covid cases (Aiyegbusi et al., 2021). This persistent and overwhelming sense of tiredness can be debilitating, hindering individuals' ability to engage in their usual activities.

In addition to fatigue, Long Covid is often characterized by cognitive impairment, commonly referred to as "brain fog." This cognitive dysfunction can manifest as difficulties with concentration, memory loss, and a sense of mental fogginess. These cognitive challenges further compound the burden of Long Covid, affecting individuals' ability to perform tasks that require mental clarity and focus.

Amnesia, or memory loss, is another symptom reported among individuals with Long Covid. This can manifest as difficulties in remembering recent events or retrieving information from the past. Such memory impairment can significantly impact individuals' daily functioning and quality of life.

Sleep disorders are also prevalent in Long Covid cases. Many individuals experience disrupted sleep patterns, including difficulties falling asleep, staying asleep, or experiencing restful sleep. These sleep disturbances can further exacerbate fatigue and contribute to overall feelings of exhaustion.

Palpitations, which refer to the awareness of one's heartbeat, are reported by some individuals with Long Covid. This sensation of a racing or irregular heartbeat can be distressing and may cause anxiety or unease.

Sore throat is another symptom that can be present in Long Covid cases. This persistent throat discomfort or irritation can be bothersome and may be accompanied by other respiratory symptoms.

It is important to recognize and acknowledge the wide range of symptoms experienced by individuals with Long Covid. By understanding and addressing these symptoms, healthcare providers can offer appropriate support and interventions to improve patients' quality of life and facilitate their recovery.

The emotional impact of Long Covid is significant and can have lasting effects on individuals' mental health. The study conducted by Aiyegbusi et al. (2021) found that at eight weeks after acute infection, nearly half of the surveyed patients (238 out of 488) reported being emotionally affected by their experiences of Long Covid. Among these individuals, 28 required further mental health care, indicating the severity of the emotional burden experienced by some Long Covid patients.

The study also highlighted the social implications of Long Covid. Patients reported a reduced ability to carry out social activities 4-6 weeks after hospitalization, leading to feelings of isolation and loneliness. This social withdrawal and the lack of support during their recovery can contribute to the deterioration of mental health in Long Covid patients.

Importantly, the study noted that mental health problems can persist even after the resolution of Long Covid symptoms. This suggests that the impact on mental well-being may extend beyond the acute phase of the illness. Additionally, the study found that women had higher odds of experiencing mental health problems related to Long Covid compared to men, indicating potential gender differences in the psychological impact of the condition.

The findings emphasize the importance of considering the mental health needs of individuals with Long Covid. Healthcare providers should be attentive to the emotional well-being of patients and provide appropriate support, including access to mental health care services when necessary. Recognizing the social and psychological

challenges faced by individuals with Long Covid is crucial for holistic care and to mitigate the long-term effects on mental health.

The impact of Long Covid on employment and workability is significant, as highlighted by the studies conducted by Aiyegbusi et al. (2021). These studies found that a substantial proportion of patients who were employed before hospitalization were unable to return to work after experiencing Long Covid.

In the first study, among 195 patients who were employed before hospitalization, 40% were unable to return to work. This indicates the substantial impact of Long Covid on individuals' ability to resume their previous employment. For those who did return to work, a quarter required adjustments such as reducing working hours or altering their duties due to health reasons.

Similarly, the second study reported that nearly 70% (38 out of 56) of previously hospitalized patients were unable to return to work three months after hospitalization. This high percentage reflects the challenges faced by individuals in reintegrating into the workforce after experiencing the effects of Long Covid.

The inability to return to work or the need for work modifications can have various consequences. Financial stress and burden can arise due to the loss of income or reduced earning capacity. This, in turn, can lead to additional stress and impact the mental and physical well-being of individuals dealing with Long Covid. The inability to perform tasks and activities as they did before the illness can also contribute to feelings of depression and a sense of loss.

It is important to recognize the implications of Long Covid on employment and workability and provide support to affected individuals. Rehabilitation programs, workplace accommodations, and vocational support services may be necessary to assist individuals in their recovery and facilitate their return to work. Addressing the financial and psychosocial challenges associated with the impact on employment can contribute to the overall well-being and quality of life of individuals affected by Long Covid.

This condition is characterized by the following symptoms:-

General symptoms	An inability to function normally due to fatigue or tiredness
	Symptoms that get worse after physical or mental

	effort (also known as “post-exertional malaise”)
	Fever
Respiratory & Heart	Shortness of breath or difficulty breathing
	Cough
	Chest Pain
	Heart palpitations (fast beating or pounding heart)
Neurological symptoms	Inability to concentrate or think clearly (also known as “brain fog ”)
	Headache
	Sleep Insomnia
	Lightheadedness when standing up (dizziness)
	Pins-and-needles feelings
	A change in taste or smell
	Anxiety or depression
Digestive symptoms	Diarrhea
	Stomach problems
Others	Joint or Muscle pain
	Rashes
	Menstrual cycle changes

(Table 1)

Drugs Used for Long Covid

AXA1125

In this study, the effects of AXA1125, an orally active mixture of amino acids, will be compared to a placebo in terms of improving muscle function and metabolism following

moderate exercise in subjects with fatigue-Predominant Post-Acute Sequelae of SARS-CoV-2. The study will also assess the safety and tolerability of AXA1125.

The study participants will be randomly assigned to receive either AXA1125 or a placebo. They will be instructed to take one dose of AXA1125 or the placebo twice daily for a duration of 28 days. The primary objective of the study is to evaluate the impact of AXA1125 on muscle function and metabolism after moderate exercise in individuals experiencing fatigue-Predominant Post-Acute Sequelae of SARS-CoV-2.

Secondary objectives of the study may include assessing changes in other symptoms related to post-acute sequelae of SARS-CoV-2, such as fatigue levels, cognitive function, and quality of life. Additionally, the study will monitor and evaluate the safety and tolerability of AXA1125 in the study participants.

By comparing the effects of AXA1125 to a placebo, this study aims to provide insights into the potential benefits of AXA1125 in improving muscle function and metabolism in individuals with fatigue-Predominant Post-Acute Sequelae of SARS-CoV-2. The findings of this study may contribute to the development of new treatment options and interventions for individuals experiencing post-acute sequelae of SARS-CoV-2, particularly those with fatigue-related symptoms.

This Phase 2 clinical trial, initiated on December 15, 2021, is being conducted in the United Kingdom. The study has enrolled a total of 41 participants to date. The primary objective of the study is to measure the change in phosphocreatine (PCr) recovery rate following moderate exercise from baseline to Week 4. The PCr recovery rate will be assessed using 31P-magnetic resonance spectroscopy (MRS).

The study aims to evaluate the effect of AXA1125, an orally active mixture of amino acids, on muscle function and metabolism in individuals with fatigue-Predominant Post-Acute Sequelae of SARS-CoV-2. The participants have been randomly assigned to receive either AXA1125 or a placebo, and they will take the assigned treatment twice daily for a duration of 28 days.

The primary outcome measure, the PCr recovery rate assessed by 31P-MRS, will provide valuable insights into the impact of AXA1125 on muscle energy metabolism following exercise. By comparing the change in PCr recovery rate between the treatment group and the placebo group, the study aims to assess the potential efficacy of AXA1125 in improving muscle function in individuals with post-acute sequelae of SARS-CoV-2.

As a Phase 2 clinical trial, this study is an important step in the development of AXA1125 as a potential treatment for individuals experiencing fatigue-related symptoms after SARS-CoV-2 infection. The findings from this study will contribute to our

understanding of the safety and effectiveness of AXA1125 and may inform further research and development in this field.

AXA1125, the orally active mixture of amino acids being studied in this clinical trial, has shown promising potential in addressing the mitochondrial dysfunction associated with post-acute sequelae of SARS-CoV-2. Mitochondrial dysfunction is believed to play a role in the persistent symptoms and fatigue experienced by individuals even after recovering from COVID-19.

The mechanism of action of AXA1125 involves reversing mitochondrial dysfunction and improving energetic efficiency. It achieves this by enhancing fatty acid oxidation, which is the process of breaking down fats to produce energy. By restoring cellular homeostasis and reducing inflammation, AXA1125 aims to address the underlying dysfunctions that contribute to the long-term effects of COVID-19.

The ability of AXA1125 to target mitochondrial dysfunction and improve energetic efficiency offers potential benefits to individuals experiencing the debilitating effects of post-acute sequelae of SARS-CoV-2. By enhancing cellular energy production and reducing inflammation, AXA1125 may help alleviate symptoms such as fatigue and improve overall well-being in patients who continue to suffer from the long-term effects of COVID-19.

The results of this clinical trial will provide valuable insights into the effectiveness and safety of AXA1125 in improving mitochondrial function and addressing the persistent symptoms associated with post-acute sequelae of SARS-CoV-2. If successful, AXA1125 may offer a potential therapeutic option for the growing number of patients experiencing long-lasting effects of COVID-19.

AT1001

The primary objective of this study is to assess the efficacy and safety of AT1001 compared to placebo in pediatric patients who have been diagnosed with SARS-CoV-2 infection and exhibit early signs of multisystem inflammatory syndrome in children (MIS-C). These patients are considered to be at high risk of disease progression.

AT1001 is being evaluated as a potential treatment option for pediatric patients with SARS-CoV-2 infection who are at risk of developing MIS-C. The study aims to determine whether AT1001 can effectively mitigate the progression of MIS-C and improve patient outcomes.

The study will assess various factors, including clinical symptoms, laboratory markers, and disease progression, to evaluate the efficacy of AT1001 compared to placebo. The safety profile of AT1001 will also be closely monitored throughout the study.

By investigating the efficacy and safety of AT1001 in this specific patient population, the study aims to provide valuable insights into the potential benefits of this treatment approach for pediatric patients with early signs of MIS-C following SARS-CoV-2 infection. The results of this study will contribute to the understanding of therapeutic options for managing MIS-C and improving outcomes in high-risk pediatric patients affected by SARS-CoV-2 infection.

In this study, AT1001 will be administered orally at a dose of 10 µg/kg/dose, up to a maximum dose of 500 µg/dose (rounded to the nearest 50 µg). The dosing frequency will be four times a day (QID). This dosing regimen will be compared to a matching placebo, both in addition to the standard of care for multisystem inflammatory syndrome in children (MIS-C).

By administering AT1001 or placebo at the specified dosage and frequency, the study aims to evaluate the efficacy and safety of AT1001 in pediatric patients with early signs of MIS-C. The administration of the study drug will be done in conjunction with the standard of care for MIS-C, ensuring that patients receive the necessary medical management for their condition.

The study will closely monitor the response to treatment, clinical outcomes, and any potential adverse effects associated with the administration of AT1001 or placebo. The goal is to assess the potential benefits of AT1001 as an adjunctive therapy for pediatric patients at high risk of disease progression in the context of MIS-C following SARS-CoV-2 infection.

This Phase 2a (Proof of Concept) clinical trial is taking place in Boston, Massachusetts. The study started in October 2021 and has enrolled 20 participants thus far. It is designed as a randomized, double-blind, placebo-controlled study.

The primary objective of this study is to evaluate the efficacy and safety of AT1001 in hospitalized pediatric patients diagnosed with multisystem inflammatory syndrome in children (MIS-C). The study aims to assess the potential benefits of AT1001 as an intervention for this specific population.

As a double-blind study, both the participants and the investigators involved are unaware of whether the patients are receiving AT1001 or a placebo. This design helps minimize bias and allows for a more objective evaluation of the study outcomes.

The study will rigorously evaluate the efficacy of AT1001 by comparing its effects against a placebo, specifically looking at its impact on the management and outcomes of MIS-C in pediatric patients. Additionally, the safety profile of AT1001 will be closely monitored throughout the trial.

Being in Phase 2 of the clinical trial process, this study is a critical step in further assessing the potential of AT1001 as a treatment option for hospitalized pediatric patients with MIS-C. The results obtained from this trial will provide valuable insights into the efficacy and safety of AT1001, contributing to the development of evidence-based approaches for managing MIS-C in this vulnerable population.

The presence of SARS-CoV-2 viral particles in the gut after respiratory infection and the subsequent release of zonulin from intestinal epithelial cells can lead to the loosening of tight junctions. This loosening of tight junctions allows for the passage of highly inflammatory viral particles into the bloodstream, leading to systemic inflammation. This mechanism is believed to play a role in triggering Multisystem Inflammatory Syndrome in Children (MIS-C).

Larazotide, a zonulin inhibitor, works by preventing the breakdown of tight junctions in the gut. By inhibiting zonulin, larazotide helps maintain the integrity of the intestinal barrier, limiting the trafficking of antigens, including viral particles, from the gut lumen into the systemic circulation. This can potentially reduce the inflammatory response triggered by the presence of SARS-CoV-2 viral particles in the gut and contribute to the management of conditions such as MIS-C.

It is important to note that the information provided here is based on the context you provided and may not encompass the entirety of the research and understanding surrounding MIS-C and larazotide. Further scientific investigations and clinical studies are needed to fully elucidate the mechanisms involved and assess the potential efficacy of larazotide or similar interventions in the context of MIS-C.

The primary objective of the study is to assess the efficacy and safety of AT1001 compared to placebo in reducing the symptoms of Multisystem Inflammatory Syndrome in Children (MIS-C). Specifically, the study aims to evaluate the proportion of participants who experience an improvement in MIS-C-related gastrointestinal (GI) symptoms and show no progression of the disease.

The study will involve comparing the effects of AT1001, a specific intervention, with a placebo control group. Participants will be monitored for changes in their GI symptoms, as well as the overall progression of the MIS-C condition. The study will also assess the safety profile of AT1001 in pediatric patients with MIS-C.

By evaluating the efficacy and safety of AT1001 in mitigating MIS-C symptoms and preventing disease progression, the study aims to provide important insights into potential treatment options for this condition. It will contribute to the understanding of how AT1001 affects GI symptoms associated with MIS-C and its overall impact on the disease course.

IMC-2

IMC-2 is a novel combination therapy consisting of valacyclovir and celecoxib. These two components have been specifically chosen due to their synergistic mechanisms of action, which aim to inhibit the activation and replication of herpes viruses. The goal of IMC-2 is to either keep herpes viruses in a dormant or latent state or to down-regulate them from an active (lytic) state back to latency.

Valacyclovir, a prodrug of acyclovir, works by inhibiting the viral DNA polymerase, which is necessary for the replication of herpes viruses. By blocking this enzyme, valacyclovir helps to prevent the multiplication of the viruses in the body.

Celecoxib, on the other hand, is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits both cyclooxygenase-2 (COX-2) and cyclooxygenase-1 (COX-1) enzymes. These enzymes are utilized by herpes viruses to accelerate their replication process. By inhibiting COX-2 and COX-1, celecoxib aims to slow down the replication of herpes viruses, reducing their activity.

The combination of valacyclovir and celecoxib in IMC-2 is designed to enhance the effectiveness of each component, targeting different stages of the herpes virus life cycle and inhibiting their replication and activation. By utilizing this dual mechanism of action, IMC-2 aims to provide a more comprehensive approach to controlling and managing herpes virus infections.

IMC-2 is a dual mechanism antiviral therapy that combines valacyclovir and celecoxib to target herpes viruses and reduce their disease burden. By merging these two medications, IMC-2 aims to inhibit the activation and replication of herpes viruses more effectively.

Valacyclovir, a prodrug of acyclovir, works by blocking the viral DNA polymerase, an essential enzyme for herpes virus replication. By inhibiting this enzyme, valacyclovir can hinder the ability of the virus to reproduce and spread.

Celecoxib, on the other hand, is a nonsteroidal anti-inflammatory drug (NSAID) that has been found to inhibit both COX-2 and COX-1 enzymes, which are utilized by herpes

viruses to promote their replication. By inhibiting these enzymes, celecoxib can impede the replication of the virus and reduce its activity.

By combining valacyclovir and celecoxib in IMC-2, the therapy takes advantage of their complementary mechanisms of action. Valacyclovir targets the viral replication process, while celecoxib acts to suppress the inflammatory response and further hinder viral replication. Together, they work synergistically to reduce the activation and replication of herpes viruses, leading to a decrease in the disease burden associated with these infections.

Overall, IMC-2 provides a comprehensive approach to managing herpes virus infections by targeting multiple aspects of the viral life cycle, ultimately aiming to reduce symptoms and improve patient outcomes.

The second development candidate of the company aims to address the wide range of symptoms associated with long Covid, including fatigue, sleep disturbances, attention difficulties, pain, autonomic dysfunction, and anxiety. This antiviral therapy is being specifically developed to target and manage these symptoms, which can have a significant impact on the quality of life for individuals experiencing long Covid.

By targeting the underlying mechanisms or pathways involved in these symptoms, the antiviral therapy aims to alleviate fatigue, improve sleep quality, enhance attention and cognitive function, reduce pain, regulate autonomic function, and alleviate anxiety symptoms. The therapy may work through various mechanisms, such as modulating neurochemical signaling, addressing inflammation, or regulating specific pathways associated with these symptoms.

The goal of this development candidate is to provide a comprehensive approach to managing the multi-faceted symptoms of long Covid, recognizing the impact these symptoms can have on individuals' daily functioning and overall well-being. By targeting these specific areas, the therapy aims to improve symptom management and potentially enhance the overall recovery and quality of life for individuals affected by long Covid.

It's important to note that the development candidate is currently undergoing research and clinical trials to assess its safety and efficacy in managing the symptoms of long Covid. Further studies and evaluations are needed to determine its effectiveness and potential benefits for individuals experiencing these symptoms.

Conclusion

Long COVID, also known as Post-Acute Sequelae of SARS-CoV-2 (PASC), is a condition that affects multiple organ systems and is associated with vascular and

clotting abnormalities. The global prevalence of long COVID has reached millions of cases, and this number continues to rise. Extensive research conducted over a span of two years has revealed that a significant portion of individuals with PASC may experience lifelong disabilities. Unfortunately, at present, there are limited diagnostic and treatment options available for this condition, emphasizing the urgent need for clinical trials to test potential treatments targeting the underlying biological mechanisms. As of now, no cure for PASC has been identified.

References

1. Aiyegbusi, O. L., Hughes, S. E., Turner, G., Rivera, S. C., McMullan, C., Chandan, J. S., . . . Calvert, M. J. (2021). Symptoms, complications and management of Long Covid: A Review. Journal of the Royal Society of Medicine, 114(9), 428-442. doi:10.1177/01410768211032850 (Aiyegbusi et al., 2021)

2. AT1001 for the Treatment of COVID-19 Related MIS-C. https://beta.clinicaltrials.gov/study/NCT05022303. Accessed January 17, 2023.

3. AXA1125 IN LONG COVID. https://axcellatx.com/pipeline/axa1125. Accessed January 17, 2023.

4. Brodin, P., Casari, G., Townsend, L., O'Farrelly, C., Tancevski, I., Löffler-Ragg, J., . . . Casanova, J. (2022). Studying severe long covid to understand post-infectious disorders beyond COVID-19. Nature Medicine, 28(5), 879-882. doi:10.1038/s41591-022-01766-7 (Brodin et al., 2022)

5. Centers for Disease Control and Prevention. Long COVID or Post-COVID Conditions. https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects/index.html. Accessed November 3, 2023.

6. Cucinotta, D., & Vanelli, M. (2020). WHO Declares COVID-19 a Pandemic. Acta bio-medica : Atenei Parmensis, 91(1), 157–160. doi:10.23750/abm.v91i1.9397 (Cucinotta et al.,2020)

7. Di Micco, S., Musella, S., Sala, M., Scala, M. C., Andrei, G., Snoeck, R., . . . Fasano, A. (2021). Peptide derivatives of the zonulin inhibitor Larazotide (AT1001) as potential anti SARS-COV-2: Molecular modelling, synthesis and

bioactivity evaluation. International Journal of Molecular Sciences, 22(17), 9427. doi:10.3390/ijms22179427 (Di Micco et al., 2021)

8. Efficacy, Safety, Tolerability of AXA1125 in Fatigue After COVID-19 Infection. https://beta.clinicaltrials.gov/study/NCT05152849. Accessed January 17, 2023.

9. Imai, K., Yamano, T., Nishi, S., Nishi, R., Nishi, T., Tanaka, H., . . . Nishi, K. (2022). Epipharyngeal abrasive therapy (EAT) has potential as a novel method for long covid treatment [Abstract]. Viruses, 14(5), 907. doi:10.3390/v14050907 (Imai et al., 2022)

10. Ledford, H. (2022). Long-Covid Treatments: Why the world is still waiting. Nature, 608(7922), 258-260. doi:10.1038/d41586-022-02140-w (Ledford, 2022)

11. Mantovani, A., Morrone, M. C., Patrono, C., Santoro, M. G., Schiaffino, S., Remuzzi, G., . . . Vineis, P. (2022). Long Covid: Where we stand and challenges ahead. Cell Death & Differentiation. doi:10.1038/s41418-022-01052-6 (Mantovani et al., 2022)

12. Nalbandian, A., Sehgal, K., Gupta, A., Madhavan, M. V., McGroder, C., Stevens, J. S., . . . Wan, E. Y. (2021). Post-acute COVID-19 syndrome. Nature Medicine, 27(4), 601-615. doi:10.1038/s41591-021-01283-z (Nalbandian et al., 2021)

13. Pears, K. (2022, June 13). Research summary-what are the current treatments being trialled for long covid?: The Me Association. Retrieved November 3, 2022, from https://meassociation.org.uk/2022/02/research-summary-what-are-the-current-treatments-being-trialled-for-long-covid/ (Pears, 2022)

14. Szarpak, L., Pruc, M., Filipiak, K. J., Popieluch, J., Bielski, A., Jaguszewski, M. J., . . . Peacock, F. W. (2022). Myocarditis: A complication of COVID-19 and long-covid-19 syndrome as a serious threat in modern cardiology. Cardiology Journal, 29(1), 178-179. doi:10.5603/cj.a2021.0155 (Szarpak et al., 2022)

15. Virios Therapeutics Announces Research Collaboration Exploring the Potential of Combination Antiviral Therapy for Treating Long COVID. https://ir.virios.com/news/press-releases/detail/72/virios-therapeutics-announces-research-collaboration. Accessed January 17, 2023.

16. Wu, F., Zhao, S., Yu, B., Chen, Y., Wang, W., Song, Z., . . . Zhang, Y. (2020). A new coronavirus associated with human respiratory disease in China. Nature, 579(7798), 265-269. doi:10.1038/s41586-020-2008-3 (Wu et al., 2020)

17. Zonulin Antagonist, Larazotide (AT1001), As an Adjuvant Treatment for Multisystem Inflammatory Syndrome in Children: A Case Series. https://journals.lww.com/ccejournal/fulltext/2022/02000/zonulin_antagonist,_larazotide__at1001_,_as_an.19.aspx. Accessed January 17, 2023.